AN EDUCATIONAL TOOL TO ESTIMATE THE PROBABILITY OF WILD-TYPE
TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (wtATTR-CM)

Developed with AI/ML algorithm using diagnosis codes from a real-world claims dataset, the Estimator highlights
different combinations of cardiac and non-cardiac symptoms of Wild-Type Transthyretin Amyloid Cardiomyopathy
(wtATTR-CM) for hypothetical patient cases with heart failure.
​​​​​​​
Try out the Estimator tool to learn more about the red flags of wild-type ATTR-CM and the associated risk to help raise
suspicion of this life-threatening disease

Register / Sign In to Access

​​​​​​​​​​​​​​
PP-VDM-SGP-0085/29OCT2021

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.